SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0007 0920 OR L773:1532 1827 "

Sökning: L773:0007 0920 OR L773:1532 1827

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Hansson, Mats G. (författare)
  • Ethics and biobanks
  • 2009
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 100:1, s. 8-12
  • Forskningsöversikt (övrigt vetenskapligt)abstract
    • Biobank research has been the focus of great interest of scholars and regulatory bodies who have addressed different ethical issues. On the basis of a review of the literature it may be concluded that, regarding some major themes in this discussion, a consensus seems to emerge on the international scene after the regular exchange of arguments in scientific journals. Broad or general consent is emerging as the generally preferred solution for biobank studies and straightforward instructions for coding will optimise privacy while facilitating research that may result in new methods for the prevention of disease and for medical treatment. The difficult question regarding the return of information to research subjects is the focus of the current research, but a helpful analysis of some of the issues at stake and concrete recommendations have recently been suggested.
  •  
32.
  • Harris, H. R., et al. (författare)
  • Alcohol intake and mortality among women with invasive breast cancer
  • 2012
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 106:3, s. 592-595
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Alcohol intake has consistently been associated with increased breast cancer incidence in epidemiological studies. However, the relation between alcohol and survival after breast cancer diagnosis is less clear.METHODS: We investigated whether alcohol intake was associated with survival among 3146 women diagnosed with invasive breast cancer in the Swedish Mammography Cohort. Alcohol consumption was estimated using a food frequency questionnaire. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs).RESULTS: From 1987 to 2008 there were 385 breast cancer-specific deaths and 860 total deaths. No significant association was observed between alcohol intake and breast cancer-specific survival. Women who consumed 10 g per day (corresponding to approximately 0.75 to 1 drinks) or more of alcohol had an adjusted HR (95% CI) of breast cancer-specific death of 1.36 (0.82-2.26; p(trend) = 0.47) compared with non-drinkers. A significant inverse association was observed between alcohol and non-breast cancer deaths. Those who consumed 3.4-9.9 g per day of alcohol had a 33% lower risk of death compared with non-drinkers (95% CI 0.50-0.90; p(trend) = 0.04).CONCLUSION: Our findings suggest that alcohol intake up to approximately one small drink per day does not negatively impact breast cancer-specific survival and a half drink per day is associated with a decreased risk of mortality from other causes.
  •  
33.
  • Harris, H R, et al. (författare)
  • Coffee and black tea consumption and breast cancer mortality in a cohort of Swedish women
  • 2012
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 107:5, s. 874-878
  • Tidskriftsartikel (refereegranskat)abstract
    • Background:Coffee and black tea contain a mixture of compounds that have the potential to influence breast cancer risk and survival. However, epidemiologic data on the relation between coffee and black tea consumption and breast cancer survival are sparse.Methods:We investigated the association between coffee and black tea consumption and survival among 3243 women with invasive breast cancer in the Swedish Mammography Cohort. Intake was estimated using a food frequency questionnaire. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs).Results:From 1987 to 2010 there were 394 breast cancer-specific deaths and 973 total deaths. Coffee and black tea were not associated with breast cancer-specific or overall mortality. Women consuming 4+ cups of coffee per day had a covariate and clinical characteristics-adjusted HR (95% CI) of death from breast cancer of 1.14 (0.71-1.83; ptrend=0.81) compared with those consuming <1 cup per day. Women consuming 2+ cups of black tea per day had a covariate and clinical characteristics-adjusted HR (95% CI) of death from breast cancer of 1.02 (0.67-1.55; ptrend=0.94) compared with non-tea drinkers. Caffeine was also not associated with breast cancer-specific (HR for top to bottom quartile=1.06; 95% CI=0.79-1.44; ptrend=0.71) or overall mortality.Conclusion:Our findings suggest that coffee, black tea, and caffeine consumption before breast cancer diagnosis do not influence breast cancer-specific and overall survival.
  •  
34.
  • Harris, H. R., et al. (författare)
  • Vitamin C intake and breast cancer mortality in a cohort of Swedish women
  • 2013
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 109:1, s. 257-264
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Vitamin C may influence cancer progression through its antioxidant properties. However, the evidence from observational epidemiologic studies on vitamin C intake and survival following breast cancer diagnosis is not consistent, and the safety of vitamin C supplements following breast cancer diagnosis has not been extensively studied. Methods: Using a food-frequency questionnaire we investigated whether vitamin C intake was associated with survival among 3405 women diagnosed with invasive breast cancer in the Swedish Mammography Cohort. Results: From 1987-2010, there were 1055 total deaths with 416 deaths from breast cancer. Women in the highest quartile of pre-diagnosis vitamin C intake had an adjusted HR (95% CI) of breast cancer death of 0.75 (0.57-0.99) compared with those in the lowest quartile (P-trend=0.03). There was a borderline significant association between vitamin C intake and total mortality (HR 0.84; 95% CI 0.71-1.00; P-trend=0.08). Among 717 breast cancer cases for whom post-diagnosis supplement use was available, there was no association between vitamin C supplement use (approximate to 1000 mg) and breast cancer-specific mortality (HR=1.06; 95% CI=0.52-2.17). Conclusion: Our findings suggest that dietary vitamin C intake before breast cancer diagnosis may be associated with breast cancer survival. In addition, post-diagnosis vitamin C supplementation at the level observed in our population was not associated with survival.
  •  
35.
  • Hellman, Kristina, et al. (författare)
  • Differential tissue-specific protein markers of vaginal carcinoma
  • 2009
  • Ingår i: British Journal of Cancer. - Cancer Research UK. - 0007-0920 .- 1532-1827. ; 100:8, s. 1303-1314
  • Forskningsöversikt (övrigt vetenskapligt)abstract
    • The objective was to identify proteins differentially expressed in vaginal cancer to elucidate relevant cancer-related proteins. A total of 16 fresh-frozen tissue biopsies, consisting of 5 biopsies from normal vaginal epithelium, 6 from primary vaginal carcinomas and 5 from primary cervical carcinomas, were analysed using two-dimensional gel electrophoresis (2-DE) and MALDI-TOF mass spectrometry. Of the 43 proteins identified with significant alterations in protein expression between non-tumourous and tumourous tissue, 26 were upregulated and 17 were downregulated. Some were similarly altered in vaginal and cervical carcinoma, including cytoskeletal proteins, tumour suppressor proteins, oncoproteins implicated in apoptosis and proteins in the ubiquitin-proteasome pathway. Three proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-hydrolase beta). The identified proteins imply involvement of multiple different cellular pathways in the carcinogenesis of vaginal carcinoma. Similar protein alterations were found between vaginal and cervical carcinoma suggesting common tumourigenesis. However, the expression level of some of these proteins markedly differs among the three tissue specimens indicating that they might be useful molecular markers.
  •  
36.
  • Hemdan, Tammer, et al. (författare)
  • The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer
  • 2014
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 111:6, s. 1180-1187
  • Tidskriftsartikel (refereegranskat)abstract
    • Background:The oncoprotein-18/stathmin 1 (STMN1), involved in cell progression and migration, is associated with clinical outcome in breast cancer. Here we aim to investigate its clinical significance in urinary bladder cancer and its possibilities as a therapeutic target.Methods:Immunohistochemical analyses of STMN1 protein expression were performed in three patient cohorts: cohort I (n=115 Ta, n=115 T1, n=112 T2-4 stages), cohort II, based on randomised controlled trials (n=239 T1-T4), and cohort III of primary tumour/matched metastasis (n=90 T1-T4). The effects of STMN1 on cell proliferation and migration were evaluated in the urinary bladder cancer cell line, T24, by inhibiting STMN1-cellular expression using siRNA.Results:In cohort I, high STMN1 expression correlated to shorter disease-specific survival hazard ratio (HR)=2.04 (95% confidence interval (CI) 1.13-3.68; P=0.02), elevated p53- (P<0.001) and Ki67-protein levels (P<0.001). The survival result was validated in cohort II: HR=1.76 (95% CI 1.04-2.99; P=0.03). In the metastatic bladder cancer material, 70% of the patients were STMN1-positive in both the primary tumour and matched metastases. In vitro, the growth and migration of the T24 cells were significantly reduced (P<0.01, P<0.0001, respectively), when transfecting the cells with STMN1-siRNA.Conclusions:STMN1 protein expression has prognostic significance but is primarily a potential treatment target in urinary bladder cancer. 
37.
  • Johansson, Birgitta, et al. (författare)
  • Health-related quality of life and distress in cancer patients : results from a large randomised study
  • 2008
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 99:12, s. 1975-1983
  • Tidskriftsartikel (refereegranskat)abstract
    • To compare the effectiveness of individual support, group rehabilitation and a combination of the two in improving health-related quality of life (HRQOL) and psychological well-being in cancer patients during 24 months after diagnosis, as compared with standard care (SC). Furthermore, to compare the study sample and a random sample of the Swedish population with regard to HRQOL. A total of 481 consecutive patients, newly diagnosed with cancer, were randomly assigned to one of the four alternatives. Data on HRQOL and psychological well-being were collected at baseline and after 3, 6, 12 and 24 months. The interventions did not improve HRQOL or psychological well-being, as compared with SC. At 3 months, the study sample reported an HRQOL comparable with the normal population. Many cancer patients are able to manage their cancer-related concerns with the support available from SC. However, it is reasonable to assume that the findings suffer from a lack of data from especially vulnerable patients and a possible Hawthorne effect. It cannot be concluded that cancer patients have no need for additional psychosocial interventions. Future projects should include screening and target interventions for those at risk for significant and prolonged psychological distress.
  •  
38.
  • Johansson, B., et al. (författare)
  • Health-related quality of life and distress in cancer patients: results from a large randomised study
  • 2008
  • Ingår i: 7th World Congress of Psycho-Oncology,Copenhagen, Denmark,2004-08-25 - 2004-08-28. - Nature Publishing Group.
  • Konferensbidrag (refereegranskat)abstract
    • To compare the effectiveness of individual support, group rehabilitation and a combination of the two in improving health-related quality of life (HRQOL) and psychological well-being in cancer patients during 24 months after diagnosis, as compared with standard care (SC). Furthermore, to compare the study sample and a random sample of the Swedish population with regard to HRQOL. A total of 481 consecutive patients, newly diagnosed with cancer, were randomly assigned to one of the four alternatives. Data on HRQOL and psychological well-being were collected at baseline and after 3, 6, 12 and 24 months. The interventions did not improve HRQOL or psychological well-being, as compared with SC. At 3 months, the study sample reported an HRQOL comparable with the normal population. Many cancer patients are able to manage their cancer-related concerns with the support available from SC. However, it is reasonable to assume that the findings suffer from a lack of data from especially vulnerable patients and a possible Hawthorne effect. It cannot be concluded that cancer patients have no need for additional psychosocial interventions. Future projects should include screening and target interventions for those at risk for significant and prolonged psychological distress.
  •  
39.
  • Kaliszczak, M, et al. (författare)
  • A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
  • 2013
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 108:2, s. 342-50
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: This study investigates whether a histone deacetylase subtype 6 (HDAC6) inhibitor could be used in the treatment of solid tumours.METHODS: We evaluated the effect of a novel inhibitor, C1A, on HDAC6 biochemical activity and cell growth. We further examined potential of early noninvasive imaging of cell proliferation by [(18)F]fluorothymidine positron emission tomography ([(18)F]FLT-PET) to detect therapy response.RESULTS: C1A induced sustained acetylation of HDAC6 substrates, α-tubulin and HSP90, compared with current clinically approved HDAC inhibitor SAHA. C1A induced apoptosis and inhibited proliferation of a panel of human tumour cell lines from different origins in the low micromolar range. Systemic administration of the drug inhibited the growth of colon tumours in vivo by 78%. The drug showed restricted activity on gene expression with <0.065% of genes modulated during 24 h of treatment. C1A treatment reduced tumour [(18)F]FLT uptake by 1.7-fold at 48 h, suggesting that molecular imaging could provide value in future studies of this compound.CONCLUSION: C1A preferentially inhibits HDAC6 and modulates HDAC6 downstream targets leading to growth inhibition of a diverse set of cancer cell lines. This property together with the favourable pharmacokinetics and efficacy in vivo makes it a candidate for further pre-clinical and clinical development.
  •  
40.
  • Larsson, A., et al. (författare)
  • Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer
  • 2011
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 105:5, s. 666-672
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer. In this study, we investigated the prognostic impact of PODXL expression in colorectal cancer (CRC). METHODS: Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a prospective, population-based cohort study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to assess the impact of PODXL expression on cancer-specific survival (CSS) and overall survival (OS). RESULTS: High PODXL expression was significantly associated with unfavourable clinicopathological characteristics, a shorter CSS (hazard ratio (HR) = 1.98; 95% confidence interval (CI) 1.38-2.84, P < 0.001) and 5-year OS (HR = 1.85; 95% CI 1.29-2.64, P = 0.001); the latter remaining significant in multivariate analysis (HR = 1.52; 95% CI 1.03-2.25, P = 0.036). In addition, in curatively resected stage III (T1-4, N1-2, M0) patients (n = 122) with tumours with high PODXL expression, a significant benefit from adjuvant chemotherapy was demonstrated (p(interaction) = 0.004 for CSS and 0.015 for 5-year OS in multivariate analysis). CONCLUSION: Podocalyxin-like 1 expression is an independent factor of poor prognosis in CRC. Our results also suggest that PODXL may be a useful marker to stratify patients for adjuvant chemotherapy.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (68)
Typ av publikation
tidskriftsartikel (643)
forskningsöversikt (4)
konferensbidrag (2)
Typ av innehåll
refereegranskat (629)
övrigt vetenskapligt (24)
Författare/redaktör
Wolk, A, (23)
Weiderpass, E, (21)
Olsson, Håkan, (20)
Auer, G, (20)
Glimelius, Bengt, (18)
Trichopoulos, D (18)
visa fler...
Trichopoulou, A (18)
Kaaks, R (17)
Hall, P, (16)
Overvad, K (15)
Adami, HO, (15)
Ekbom, A (15)
Hemminki, K (15)
Lagergren, J, (15)
Tjonneland, A (14)
Riboli, E (14)
Sánchez, M-J (14)
Boeing, H (13)
Ye, W. (13)
Tumino, R (13)
Khaw, K-T (13)
Holmberg, Lars, (12)
Lindblom, A, (12)
Andersson, S (12)
Palli, D (12)
Ahlman, Håkan, 1947- ... (12)
Pukkala, E (11)
Boffetta, P (11)
Nyren, O, (11)
Czene, K, (11)
Dillner, J, (10)
Nilsson, Ola, 1957-, (10)
Steineck, G, (10)
Bueno-de-Mesquita, H ... (9)
Ardanaz, E (9)
Lagiou, P (9)
Adolfsson, J. (9)
Glimelius, B (9)
Rodriguez, L. (9)
Jernström, Helena (9)
Blomqvist, Carl, (8)
Aaltonen, LA (8)
Clavel-Chapelon, F (8)
Kogner, P, (8)
Hansson, J. (8)
Peterlongo, P (8)
Feychting, M, (8)
Wängberg, Bo, 1953-, (8)
Sundquist, Jan, (8)
Larrañaga, N (8)
visa färre...
Lärosäte
Karolinska Institutet (409)
Lunds universitet (154)
Uppsala universitet (112)
Umeå universitet (71)
Göteborgs universitet (55)
Linköpings universitet (46)
visa fler...
Örebro universitet (15)
Kungliga Tekniska Högskolan (4)
Mälardalens högskola (4)
Malmö universitet (4)
Chalmers tekniska högskola (3)
Stockholms universitet (2)
Högskolan i Jönköping (2)
Mittuniversitetet (1)
Södertörns högskola (1)
visa färre...
Språk
Engelska (647)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (356)
Naturvetenskap (11)
Samhällsvetenskap (3)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy